BofA analyst Tazeen Ahmad raised the firm’s price target on Merus to $80 from $61 and keeps a Buy rating on the shares after the company reported 67% objective response rate, or ORR, in 24 evaluable first-line head and neck squamous cell carcinoma, or HNSCC, patients treated with petosemtamab in combination with pembrolizumab. The results are “highly encouraging” and increase BofA’s confidence in the potential for peto’ in that line of treatment, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus N.V. Announces Proposed Public Offering of Common Shares
- Merus announces interim clinical data on petosemtamab with pembrolizumab
- Merus data coming early nothing to be worried about, says Truist
- Merus abstract shows ‘stellar potential’ of petosemtamab, says H.C. Wainwright
- Merus price target raised to $61 from $52 at BofA